Your browser doesn't support javascript.
loading
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
Ella, Raches; Reddy, Siddarth; Blackwelder, William; Potdar, Varsha; Yadav, Pragya; Sarangi, Vamshi; Aileni, Vinay K; Kanungo, Suman; Rai, Sanjay; Reddy, Prabhakar; Verma, Savita; Singh, Chandramani; Redkar, Sagar; Mohapatra, Satyajit; Pandey, Anil; Ranganadin, Pajanivel; Gumashta, Raghavendra; Multani, Manish; Mohammad, Shameem; Bhatt, Parul; Kumari, Laxmi; Sapkal, Gajanan; Gupta, Nivedita; Abraham, Priya; Panda, Samiran; Prasad, Sai; Bhargava, Balram; Ella, Krishna; Vadrevu, Krishna Mohan.
Afiliação
  • Ella R; Bharat Biotech International, Hyderabad, India.
  • Reddy S; Bharat Biotech International, Hyderabad, India.
  • Blackwelder W; WB Statistical Consulting, Bethesda, MA, USA.
  • Potdar V; National Institute of Virology, Indian Council of Medical Research, Pune, India.
  • Yadav P; National Institute of Virology, Indian Council of Medical Research, Pune, India.
  • Sarangi V; Bharat Biotech International, Hyderabad, India.
  • Aileni VK; Bharat Biotech International, Hyderabad, India.
  • Kanungo S; National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkatta, India.
  • Rai S; All India Institute of Medical Sciences, New Delhi, India.
  • Reddy P; Nizams Institute of Medical Sciences, Hyderabad, India.
  • Verma S; Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India.
  • Singh C; All India Institute of Medical Sciences, Patna, India.
  • Redkar S; Redkar Hospital, Panjim, India.
  • Mohapatra S; SRM Hospital and Research Centre, Chennai, India.
  • Pandey A; ESIC Medical College and Hospital, Faridabad, India.
  • Ranganadin P; Mahatma Gandhi Medical College and Research Institute, Pondicherry, India.
  • Gumashta R; Department of Community Medicine, People's College of Medical Sciences and Research Centre, People's University, Bhopal, India.
  • Multani M; Rahate Surgical Hospital, Nagpur, India.
  • Mohammad S; Aligarh Muslim University, Aligarh, India.
  • Bhatt P; GMERS Medical College and Civil Hospital, Ahmedabad, India.
  • Kumari L; Government Fever Hospital, Guntur, India.
  • Sapkal G; National Institute of Virology, Indian Council of Medical Research, Pune, India.
  • Gupta N; Indian Council of Medical Research, New Delhi, India.
  • Abraham P; National Institute of Virology, Indian Council of Medical Research, Pune, India.
  • Panda S; Indian Council of Medical Research, New Delhi, India.
  • Prasad S; Bharat Biotech International, Hyderabad, India.
  • Bhargava B; Indian Council of Medical Research, New Delhi, India.
  • Ella K; Bharat Biotech International, Hyderabad, India.
  • Vadrevu KM; Bharat Biotech International, Hyderabad, India. Electronic address: kmohan@bharatbiotech.com.
Lancet ; 398(10317): 2173-2184, 2021 12 11.
Article em En | MEDLINE | ID: mdl-34774196
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas de Produtos Inativados / Imunogenicidade da Vacina / Vacinas contra COVID-19 / COVID-19 / Eficácia de Vacinas Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas de Produtos Inativados / Imunogenicidade da Vacina / Vacinas contra COVID-19 / COVID-19 / Eficácia de Vacinas Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male País/Região como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article